BIO International 2025: Sweden's Alligator has a phase three ready CD40 asset for pancreatic cancer and is looking for a partner to move it forward

CEO Søren Bregenholt describes Alligators phase 2 data, as well as regulatory feedback it has received regarding the phase three trial design. He desribes looking for a partner, and what other cancers the therapy could have utility in. Plus, a next-generation bi-specific targeting CD40 and CEACAM5.